A Deep Learning Pathomic Signature Predicts Survival and Recurrence in Pancreatic Ductal Adenocarcinoma Independent of CA19-9 🧪 #PancreatiCancer www.sciencedirect.com/science/arti...
Large-scale multiomic analysis identifies non-coding somatic driver mutations and nominates ZFP36L2 as a driver gene for pancreatic ductal adenocarcinoma #PancreatiCancer 🧪 gut.bmj.com/cgi/content/...
Multi-stromal organoid co-cultures model pancreatic cancer and pancreatitis epithelial cell-fibroblast heterogeneity #PancreatiCancer 🧪 www.biorxiv.org/content/10.6...
KRAS inhibition (together with other substances) will be a breakthrough in the treatment of #pancreaticancer
Can one target quiescent Pancreatic stellate cells (PSCs) to modify the development of #diabetes associated #pancreaticancer insight.jci.org/articles/vie...?
Published in #BJC, our 🌎 study with 935 localized #pancreaticancer patients after resection, comparing preoperative FFX vs GnP:
📎FFX vs GnP not associated with OS (p=0.17)
📎Effect FFX ⬆️ if lower serum CA19.9 #tumorbiology
🚨Pragmatic RCT #chemosensitivitymarkers🔍
👉 www.nature.com/articles/s41...
NEW EPISODE! This week, we are talking about the results of NRG-RTOG 0408 & the history of #pancreaticancer research. #CancerResearch #PanCANPurpleStride
Spotify: ow.ly/ocsB50VHVCE
Apple: ow.ly/QSvw50VHVCG
Amazon: ow.ly/gYEc50VHVCF
YouTube: ow.ly/AYpb50VHVCH
This trial using the radioprotective agent #amifostine in a novel, novel non-invasive formulation, then using #pancreaticancer as the „model“ tumour entity is innovative indeed.